JP2021533197A5 - - Google Patents
Info
- Publication number
- JP2021533197A5 JP2021533197A5 JP2021529257A JP2021529257A JP2021533197A5 JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5 JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex
- transferrin receptor
- complex according
- receptor antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006544A JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713959P | 2018-08-02 | 2018-08-02 | |
| US62/713,959 | 2018-08-02 | ||
| PCT/US2019/044960 WO2020028841A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating pompe disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Division JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533197A JP2021533197A (ja) | 2021-12-02 |
| JP2021533197A5 true JP2021533197A5 (enExample) | 2022-08-10 |
Family
ID=69230844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529257A Pending JP2021533197A (ja) | 2018-08-02 | 2019-08-02 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210317226A1 (enExample) |
| EP (1) | EP3830127A4 (enExample) |
| JP (2) | JP2021533197A (enExample) |
| KR (1) | KR20210054513A (enExample) |
| CN (2) | CN118662653A (enExample) |
| CA (1) | CA3108285A1 (enExample) |
| EA (1) | EA202190417A1 (enExample) |
| IL (1) | IL280483A (enExample) |
| WO (1) | WO2020028841A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| WO2021226107A1 (en) * | 2020-05-05 | 2021-11-11 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2024002753A (es) | 2021-09-01 | 2024-05-20 | Biogen Ma Inc | Anticuerpos anti receptor de transferrina y usos de los mismos. |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| IL318627A (en) * | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004094647A2 (en) * | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| EP3146050B1 (en) * | 2014-05-23 | 2020-08-12 | Genzyme Corporation | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
| KR20250133801A (ko) * | 2015-12-08 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
| MY200252A (en) * | 2016-04-18 | 2023-12-16 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| US20190240346A1 (en) * | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
-
2019
- 2019-08-02 CA CA3108285A patent/CA3108285A1/en active Pending
- 2019-08-02 EA EA202190417A patent/EA202190417A1/ru unknown
- 2019-08-02 CN CN202410663435.8A patent/CN118662653A/zh active Pending
- 2019-08-02 KR KR1020217005994A patent/KR20210054513A/ko active Pending
- 2019-08-02 US US17/265,016 patent/US20210317226A1/en not_active Abandoned
- 2019-08-02 WO PCT/US2019/044960 patent/WO2020028841A1/en not_active Ceased
- 2019-08-02 JP JP2021529257A patent/JP2021533197A/ja active Pending
- 2019-08-02 EP EP19844183.4A patent/EP3830127A4/en active Pending
- 2019-08-02 CN CN201980064590.5A patent/CN112912399A/zh active Pending
-
2021
- 2021-01-28 IL IL280483A patent/IL280483A/en unknown
-
2025
- 2025-01-17 JP JP2025006544A patent/JP2025071093A/ja active Pending